治疗前肠道完整性较低与抗逆转录病毒治疗期间脂肪增加独立相关
在未接受抗逆转录病毒治疗(ART)的HIV感染者中,随机接受三种ART方案并随访96周,评估肠道完整性标志物变化及其与脂肪、胰岛素抵抗的关联。结果发现I-FABP整体升高1.7倍且组间无差异,RAL组zonulin较蛋白酶抑制剂组升高更明显,基线I-FABP较高与内脏脂肪、总脂肪及BMI增加相关。
要点
- 未治疗HIV感染者启动ART后96周内I-FABP整体升高1.7倍,组间无差异。
- RAL方案组zonulin水平较蛋白酶抑制剂方案组升高更明显(第96周P=0.02)。
- 基线I-FABP较高与96周内脏脂肪、总脂肪及BMI增加相关。
核心结论
- ART会引起肠道屏障功能障碍标志物变化,但其改善或恶化肠道屏障功能的程度仍不明确。
- 未治疗个体中肠道屏障功能障碍标志物可预测治疗启动后总脂肪和内脏腹部脂肪增加。
研究设计与样本
- HIV感染且未接受ART的参与者随机接受替诺福韦二吡呋酯/恩曲他滨联合阿扎那韦/利托那韦、达芦那韦/利托那韦或拉替拉韦(RAL)治疗。
- 评估肠道完整性标志物zonulin、脂多糖结合蛋白(LBP)、肠脂肪酸结合蛋白(I-FABP)和回肠胆汁酸结合蛋白(I-BABP)在96周内的变化。
- 采用Wilcoxon秩和检验比较组间变化,线性回归模型量化肠道标志物与胰岛素抵抗、BMI及内脏、皮下和总脂肪组织(VAT、SAT、TAT)的关联。
主要发现
- 90%为男性,48%为非西班牙裔白人,中位年龄36岁,HIV-1 RNA为4.56 log10拷贝/mL,CD4计数为338个/µL。
- 96周内I-FABP整体增加1.7倍,组间无差异。
- 与蛋白酶抑制剂方案组相比,RAL组zonulin水平升高(第96周P=0.02);I-BABP或LBP水平变化极小。
- 基线I-FABP较高与96周VAT、TAT和BMI增加相关(分别增加16%、9%和2.5%,P<0.04)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fat accumulation and insulin resistance remain a threat to the success of antiretroviral therapy (ART). The role of gut dysfunction in metabolic complications associated with ART initiation is unclear. METHODS: Human immunodeficiency virus (HIV)-infected ART-naive participants were randomized to tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir (RAL). Changes in the gut integrity markers zonulin, lipopolysaccharide-binding protein (LBP), and intestinal fatty acid and ileal bile acid binding proteins (I-FABP and I-BABP) were assessed over 96 weeks. Wilcoxon rank-sum tests were used to compare changes between groups and linear regression models to quantify associations between gut markers, insulin resistance, body mass index (BMI), and visceral, subcutaneous, and total adipose tissue (VAT, SAT, and TAT). RESULTS: : 90% were male and 48% were White non-Hispanic. The median age was 36 years, HIV-1 ribonucleic acid was 4.56 log10 copies/mL, and CD4 count was 338 cells/µL. An overall 1.7-fold increase in I-FABP was observed throughout 96 weeks, with no difference between arms. Zonulin levels increased with RAL compared to protease inhibitor-based regimens (week 96, P = .02); minimal changes in I-BABP or LBP levels were observed. Higher baseline I-FABP levels were associated with increases in VAT, TAT, and BMI (16%, 9%, and 2.5%, respectively; P < .04) over 96 weeks. CONCLUSIONS: While ART induces changes in the markers of gut barrier dysfunction, the extent to which they improve or worsen the gut barrier function remains unclear. Nevertheless, markers of gut barrier dysfunction in ART-naive individuals predict increases in total and visceral abdominal fat with treatment initiation.
引用
- El Kamari V, Moser C, Hileman CO, et al. Lower Pretreatment Gut Integrity Is Independently Associated With Fat Gain on Antiretroviral Therapy. Clin Infect Dis. 2019. PMID: 30137242. doi:10.1093/cid/ciy716
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。